Showing results (1-10 of 9) with videos related to
Sort By:
Pageof 1
Therapeutic Drug Monitoring|August 15, 2000
Evaluation of analytical and clinical performance of a dual-probe phenotyping method for CYP2D6 polymorphism and CYP3A4 activity screeningJ Wieling, W J Tamminga, E P Sakiman, et al.Journal of Chromatography. A|April 12, 1996
Rational experimental design for bioanalytical methods validation. Illustration using an assay method for total captopril in plasmaJ Wieling, G Hendriks, W J Tamminga, et al.Seminars in Thrombosis and Hemostasis|August 10, 1999
Clopidogrel, a novel antiplatelet agent, and digoxin: absence of pharmacodynamic and pharmacokinetic interactionP A Peeters, H J Crijns, W J Tamminga, et al.European Journal of Clinical Pharmacology|February 7, 2002
The prevalence of CYP2D6 and CYP2C19 genotypes in a population of healthy Dutch volunteersW J Tamminga, J Wemer, B Oosterhuis, et al.European Journal of Clinical Pharmacology|June 24, 1999
CYP2D6 and CYP2C19 activity in a large population of Dutch healthy volunteers: indications for oral contraceptive-related gender differencesW J Tamminga, J Wemer, B Oosterhuis, et al.British Journal of Clinical Pharmacology|June 26, 2001
Mephenytoin as a probe for CYP2C19 phenotyping:effect of sample storage, intra-individual reproducibility and occurrence of adverse eventsW J Tamminga, J Wemer, B Oosterhuis, et al.European Journal of Clinical Pharmacology|June 22, 2001
An optimized methodology for combined phenotyping and genotyping on CYP2D6 and CYP2C19W J Tamminga, J Wemer, B Oosterhuis, et al.Journal of Cardiovascular Pharmacology|October 17, 2001
Inhibitory effect of telmisartan on the blood pressure response to angiotensin II challengeJ Stangier, C A Su, P N van Heiningen, et al.Journal of Clinical Pharmacology|February 24, 2001
Absorption, metabolism, and excretion of intravenously and orally administered [14C]telmisartan in healthy volunteersJ Stangier, J Schmid, D Türck, et al.Pageof 1